Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ivosidenib in Acute Myeloid Leukemia: NCT07006688 Clinical Landscape Report 2026
15 October 2026
NCT07006688 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in IDH1 Mutation Acute Myeloid Leukemia: NCT07007949 Clinical Landscape Report 2026
15 October 2026
NCT07007949 clinical landscape for IDH1 Mutation Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Atezolizumab in Relapsing acute myeloid leukemia: NCT07011004 Clinical Landscape Report 2026
15 October 2026
NCT07011004 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Linvoseltamab-gcpt in Extramedullary Disease in Multiple Myeloma: NCT07009899 Clinical Landscape Report 2026
15 October 2026
NCT07009899 clinical landscape for Extramedullary Disease in Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
YK012 in Systemic Lupus Erythematosus: NCT07010835 Clinical Landscape Report 2026
15 October 2026
NCT07010835 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine/Cedazuridine in Relapsing acute myeloid leukemia: NCT07012044 Clinical Landscape Report 2026
15 October 2026
NCT07012044 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Maribavir in High grade B-cell lymphoma: NCT07014319 Clinical Landscape Report 2026
15 October 2026
NCT07014319 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ABSK-043 in Sarcoma: NCT07014137 Clinical Landscape Report 2026
15 October 2026
NCT07014137 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dostarlimab-gxly in Endometrial Carcinoma: NCT07013851 Clinical Landscape Report 2026
15 October 2026
NCT07013851 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT07011849 Clinical Landscape Report 2026
15 October 2026
NCT07011849 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SSGJ-709 in Hepatocellular Carcinoma: NCT07016490 Clinical Landscape Report 2026
15 October 2026
NCT07016490 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cabozantinib (s)-Malate in Metastatic Clear Cell Renal Cell Carcinoma: NCT07011719 Clinical Landscape Report 2026
15 October 2026
NCT07011719 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…